Skip to main content
. 2018 Jun 7;8:70. doi: 10.1186/s13613-018-0399-1

Table 2.

Secondary outcome parameters

Secondary outcome parameters Nicotine replacement therapy (N = 21) Control group (N = 26) p value
ICU length of stay (h), median (IQR)
 Day 30 186 (127 to 278) 246 (88 to 694) 0.41
 Day 90 186 (127 to 278) 246 (88 to 694) 0.392
Hospital length of stay (h), median (IQR)
 Day 30 313 (226 to 528) 408 (220 to 720) 0.356
 Day 90 313 (226 to 528) 408 (220 to 885) 0.369
Mechanical ventilation-free hours at day 30, median (IQR) 559 (494 to 605) 515 (135 to 606) 0.152
Mechanical ventilation > 48 h, n (%) 17 (81) 20 (77)
Only non-invasive ventilation, n (%) 2 (10) 1 (4)
Nosocomial infections, n (%) 7 (24) 22 (76) 0.285
Hours with delirium, median (IQR) 8 (0 to 44) 16 (0 to 86) 0.152
RASS score, median (IQR) − 1.0 (− 2.1 to − 0.2) − 1.3 (− 2.3 to − 0.7) 0.266
 Highest score 1 (0 to 1) 1 (0 to 1) 0.615
 Lowest score − 4 (− 5 to − 2.5) − 5 (− 5 to − 4) 0.132
 Outside optimal range (h) 40 (0 to 64) 48 (14 to 122) 0.202
Physical restraint (h), median (IQR) 12.0 (0 to 85.5) 44.5 (0 to 123) 0.417
Self-removed devices, n (%)
 Self-extubations 1 (20) 4 (80) 0.245
 Catheters 24 (40) 36 (60) 0.886
Total dose of haloperidol (mg), median (IQR) 9 (0 to 24.5) 19.5 (3.25 to 31) 0.185
Serious adverse events, n 4 11 0.129
Adverse events, n
 Electrolyte disturbances 36 49
 Gastrointestinal 27 40
Cardiovascular 16 43
 Arrhythmia 5 19
 Hypo-/hypertension 10 18
 Cardiac ischaemia 1 5
 Elevated cardiac enzymes 0 1
Pulmonary 5 8
Renal 1 6
Othersa 17 31
Total adverse events, n (%) 102 (37) 177 (63) 0.096

NRT nicotine replacement therapy, RASS Richmond Agitation Sedation Scale, mg milligram, h hours, catheters are urinary and vascular catheters and nasogastric tubes

aOthers: fever, fungal infection, sinusitis, allergic reaction, skin lesion, subcutaneous emphysema, thrombocytopenia, anaemia, pancytopenia, bleeding, hypo-/hyperthermia, hypothyroidism, ICU-acquired weakness, hypoventilation (hypercapnia), hemiplegia, anxiety